Dr Dana C Hilt, Actinogen’s Chief Medical Officer, said: “Thanks to the extensive data pointing to an active target dose range of 5 to 10mg daily, we are confident that the current phase 2 clinical trials studying 10mg daily vs. placebo can generate the confirmatory data needed to progress into further pivotal trials and toward eventual regulatory approvals.”
Note.." CONFIDENT "
ACW Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
